Skip to main content

Table 2 Effect modification on hHF between dapagliflozin and empagliflozin by history of established ASCVD

From: Differences in outcomes of hospitalizations for heart failure after SGLT2 inhibitor treatment: effect modification by atherosclerotic cardiovascular disease

  Dapagliflozin Empagliflozin Dapagliflozin vs. empagliflozin
within the strata of ASCVD (+) and ASCVD (−)
ASCVD (+) 1.12 (0.87–1.45) 1 (reference) 1.12 (0.87–1.45)
ASCVD (-) 0.21 (0.15–0.28) 0.31 (0.24–0.40) 0.67 (0.49–0.90)
ASCVD (+) vs. ASCVD (−) within the strata of dapagliflozin and empagliflozin 5.47 (4.08–7.33) 3.24 (2.48–4.23)  
  1. *Test for interaction: 0.0097